Angina Pectoris Drugs Market Report

Angina Pectoris Drugs Market Analysis, By Therapeutic Class (Beta Blockers, Calcium Antagonists, Anticoagulants, Antiplatelet, Nitrates, ACE inhibitors, Ranolazine), By Major Markets, And Segment Forecasts, 2016 - 2022

  • Published Date: Nov, 2017
  • Base Year for Estimate: 2016
  • Report ID: GVR-2-68038-045-3
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 85

Industry Insights

The global angina pectoris drugs market size was valued at USD 8.5 Billion in 2016 and is expected to grow at a CAGR of 3.2% during the forecast period. The U.S. dominated angina pectoris drugs market among the seven major countries. The global angina pectoris market is expected to be collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.

Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work. 

U.S. angina pectoris drugs market

Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris. We estimate annual risk of associated non-fatal myocardial infarction (MI) and death at 3% and 1.0-2.0% respectively. The prevalence of angina rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74 and from 0.1- 1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74.

Therapeutic Class Insights

The angina pectoris drug market is commercially meaningful, however branded sales are in decline as generics dominate a larger portion of prescriptions. Though the market is fragmented, key players such as Sanofi, Gilead, AstraZeneca and Pfizer hold significant market positions. Rising geriatric population in territories such as China will influence the demand for angina pectoris drugs in the coming years.

The drug space can be divided into various therapeutic classes such as Beta Blockers, Calcium Antagonists, Anti-Platelets, Anticoagulants, Nitrates and Ranolazine. The Beta Blocker market now is predominately generic with key patent expirations impacting GlaxoSmithKline’s Coreg and AstraZeneca’s Toprol. Post Pfizer’s Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic as well.

Pipeline Insights

Novel targets and therapies gaining traction include Factor Xa Inhibitors, monoclonal antibodies and gene therapy. Some prominent players covered in the segment include Amgen, Taxus Cardium Pharmaceuticals, LegoChem Biosciences, Lee’s Pharmaceutical Holdings, Milestone Pharmaceuticals, Juventas Therapeutics, ViroMed, and Kuhnil Pharmaceutical.

Changing regulatory scenario in the U.S. and EU is anticipated to impact clinical trials of Advanced Therapy Medicinal Products. Multiple gene therapy products in Phase II/III trials are emerging as a novel approach towards addressing the need for non-surgical cardiovascular treatments. Taxus Cardium’s adenovector (serotype 5) DNA-based gene therapy is undergoing late stage clinical trials and could present promising growth opportunities for the market in the next few years.

Global angina pectoris drugs market

Regional Insights

The U.S. dominated the space by accounting for more than 33.0% of the market share in 2016. Established healthcare infrastructure, increased adoption of therapeutics and presence of key manufacturers in the U.S are responsible for its large share. Moreover, increasing incidence of cardiac disorders due to sedentary lifestyle and favorable regulatory initiatives are fueling the market growth.

China offers strong opportunity for market expansion due to removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform, and supportive 12th Five-Year Plan measures which target biotechnology as key development sector. Furthermore, presence of a large target population and strong unmet clinical needs are some of the factors that are expected to propel the growth of this region.

Competitive Insights

Some of the key players operating in this industry are Sanofi, Gilead, AstraZeneca, Pfizer, Eli Lilly, Amgen and GlaxoSmithKline. The companies are focusing on business expansion in emerging markets or developing regions such as China by adopting strategies including mergers & acquisitions for development of new products.

Biosimilar development is emerging as a promising market opportunity in angina therapeutics. Multiple enoxaparin sodium and abciximab biosimilars have gained approvals in the U.S., European and Indian markets.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2022

Market representation

Revenue in USD Million & CAGR from 2016 to 2022

Country scope

U.S., U.K., Germany, Spain, Italy, France, Japan

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report provides an analysis on the market trends in each sub-category as well as forecasts revenue growth 2014 to 2022. For this study, Grand View Research has segmented the angina therapeutics market based on therapeutic class:

  • Therapeutic Class Outlook (% market share; 2016 - 2022)

    • Beta Blockers

    • Calcium Antagonists

    • Anticoagulants

    • Anti-Platelets

    • Others

      • Nitrates

      • Anti-anginal (Ranolazine)

      • ACE inhibitors

  • Regional Outlook (% market share; 2016 - 2022)

    • U.S.

    • U.K.

    • France

    • Germany

    • Italy

    • Spain

    • Japan 

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified